文献速递眼底病与葡萄膜炎

口服抗氧化剂与叶黄素/玉米黄素补充剂延缓年龄相关性黄斑变性中地图样萎缩向中心凹进展

Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration.
PubMed 文献 · Ophthalmology · 2024-07-16

该研究为AREDS与AREDS2随机安慰剂对照试验的事后分析,共纳入392只眼(AREDS)和1210只眼(AREDS2)伴地图样萎缩的眼。结果显示,在非中心性地图样萎缩眼中,随机分配至抗氧化剂或叶黄素/玉米黄素组较未使用者,基于接近度的向中心凹进展速度显著减慢;而基于面积的进展在组间无显著差异。结论认为口服微量营养素补充可能通过增强中心凹豁免现象来延缓地图样萎缩向中心黄斑进展。

要点

  • AREDS非中心性地图样萎缩眼中,抗氧化剂组向中心凹进展为50.7 μm/年 vs 未使用组72.9 μm/年(P=0.012)。
  • AREDS2非中心性地图样萎缩眼中,叶黄素/玉米黄素组向中心凹进展为80.1 μm/年 vs 未使用组114.4 μm/年(P=0.011)。
  • 基于面积的进展在抗氧化剂组与未使用组(P=0.63)及叶黄素/玉米黄素组与未使用组(P=0.64)间均无显著差异。

核心结论

  • 口服微量营养素补充剂延缓了地图样萎缩向中心黄斑的进展,可能通过增强中心凹豁免这一自然现象实现。

研究设计与样本

  • AREDS与AREDS2均为多中心随机安慰剂对照试验,采用2×2析因设计,本文为事后分析。
  • AREDS纳入392只眼(318名参与者)伴地图样萎缩,AREDS2纳入1210只眼(891名参与者)伴地图样萎缩。
  • AREDS参与者随机分配至口服抗氧化剂(500 mg维生素C、400 IU维生素E、15 mg β-胡萝卜素)、80 mg锌、联合组或安慰剂。
  • AREDS2参与者随机分配至10 mg叶黄素/2 mg玉米黄素、350 mg二十二碳六烯酸/650 mg二十碳五烯酸、联合组或安慰剂。
  • 同意的AREDS2参与者还被随机分配至替代AREDS配方:原始配方;无β-胡萝卜素;25 mg锌替代80 mg锌;两者兼具。

主要发现

  • AREDS非中心性地图样萎缩眼(n=208)中,抗氧化剂组基于接近度的向中心黄斑进展为50.7 μm/年(95%CI 38.0-63.4),未使用组为72.9 μm/年(95%CI 61.3-84.5),P=0.012。
  • AREDS2非中心性地图样萎缩眼中,分配至无β-胡萝卜素AREDS抗氧化剂的参与者(n=325只眼),叶黄素/玉米黄素组基于接近度的进展为80.1 μm/年(95%CI 60.9-99.3),未使用组为114.4 μm/年(95%CI 96.2-132.7),P=0.011。
  • AREDS任何地图样萎缩眼(n=392)中,抗氧化剂组与未使用组基于面积的进展无显著差异(P=0.63)。
  • AREDS2任何地图样萎缩眼中,分配至无β-胡萝卜素AREDS抗氧化剂的参与者(n=505只眼),叶黄素/玉米黄素组与未使用组基于面积的进展无显著差异(P=0.64)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether oral micronutrient supplementation slows geographic atrophy (GA) progression in age-related macular degeneration (AMD). DESIGN: Post hoc analysis of Age-Related Eye Disease Study (AREDS) and AREDS2, multicenter randomized placebo-controlled trials of oral micronutrient supplementation, each with 2 × 2 factorial design. PARTICIPANTS: A total of 392 eyes (318 participants) with GA in AREDS and 1210 eyes (891 participants) with GA in AREDS2. METHODS: The AREDS participants were randomly assigned to oral antioxidants (500 mg vitamin C, 400 IU vitamin E, 15 mg β-carotene), 80 mg zinc, combination, or placebo. The AREDS2 participants were randomly assigned to 10 mg lutein/2 mg zeaxanthin, 350 mg docosahexaenoic acid/650 mg eicosapentaenoic acid, combination, or placebo. Consenting AREDS2 participants were also randomly assigned to alternative AREDS formulations: original; no beta-carotene; 25 mg zinc instead of 80 mg; both. MAIN OUTCOME MEASURES: (1) Change in GA proximity to central macula over time and (2) change in square root GA area over time, each measured from color fundus photographs at annual visits and analyzed by mixed-model regression according to randomized assignments. RESULTS: In AREDS eyes with noncentral GA (n = 208), proximity-based progression toward the central macula was significantly slower with randomization to antioxidants versus none, at 50.7 μm/year (95% confidence interval [CI], 38.0-63.4 μm/year) versus 72.9 μm/year (95% CI, 61.3-84.5 μm/year; P = 0.012), respectively. In AREDS2 eyes with noncentral GA, in participants assigned to AREDS antioxidants without β-carotene (n = 325 eyes), proximity-based progression was significantly slower with randomization to lutein/zeaxanthin versus none, at 80.1 μm/year (95% CI, 60.9-99.3 μm/year) versus 114.4 μm/year (95% CI, 96.2-132.7 μm/year; P = 0.011), respectively. In AREDS eyes with any GA (n = 392), area-based progression was not significantly different with randomization to antioxidants versus none (P = 0.63). In AREDS2 eyes with any GA, in participants assigned to AREDS antioxidants without β-carotene (n = 505 eyes), area-based progression was not significantly different with randomization to lutein/zeaxanthin versus none (P = 0.64). CONCLUSIONS: Oral micronutrient supplementation slowed GA progression toward the central macula, likely by augmenting the natural phenomenon of foveal sparing. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Keenan TDL, Agrón E, Keane PA, et al. Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration. Ophthalmology. 2024. PMID: 39025435. doi:10.1016/j.ophtha.2024.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。